Oragenics Inc is a biotechnology company focused on the development of innovative solutions for infectious diseases and oral health. The company is primarily engaged in creating novel antibiotics and therapeutics, particularly against multi-drug resistant pathogens, as well as products aimed at enhancing oral health through advanced microbial therapies. Oragenics leverages its proprietary technologies and research capabilities to address significant medical needs, with a mission to improve patient outcomes and combat rising antibiotic resistance through targeted and effective treatment options.
Oragenics (NYSE American: OGEN), a company specializing in brain-related health treatments, will present at the Centurion One Capital 2nd Annual Bahamas Summit on Oct. 22-23, 2024. President Michael Redmond will deliver a corporate presentation and participate in a Q&A session at 1:20 p.m. ET on Oct. 22 at the Rosewood Baha Mar Hotel in Nassau, Bahamas.
Oragenics (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, has released a corporate update. Highlights of shareholder report include an overview of key milestones reached this year as the company has developed its lead candidate, ONP-002, a first-in-class neurosteroid designed for the treatment of concussions. Those milestones include strengthening the company’s clinical leadership, preparing for a phase 2 clinical trial, successful cardiotoxicity testing and required genotoxicity studies and establishing a key partnership with Avance Clinical, a leading contract research organization (“CRO”).
Oragenics completed a key study showing its nasal spray drug ONP-002 effectively targets brain-related nasal areas, setting the stage for Phase 2 trials in concussion treatment.
Oragenics Inc. (NYSE American: OGEN) has successfully completed a key FDA-recognized study for its concussion treatment drug, ONP-002. Delivered via a nasal spray, ONP-002 demonstrated the ability to target areas within the nose directly linked to the brain, increasing the likelihood of reaching the brain quickly after an injury. The study, utilizing an FDA-approved intranasal casting model, paves the way for Phase II trials where ONP-002 will be administered to concussion patients within eight hours of injury. Oragenics’ breakthrough aims to fill the unmet need for pharmaceutical treatment in concussion care.
Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced the closing of its previously announced public offering. The offering consisted of 3,078,378 shares of the company’s common stock at an offering price of $0.55 per unit and pre-funded warrants to purchase up to 5,028,206 shares of common stock at $0.549 per unit. The offering raised approximately $4.45 million in gross proceeds before deductions, with the company planning to use the net proceeds to fund the continued development of its ONP-002 product candidate and for general corporate purposes and working capital. Dawson James Securities, Inc. acted as the sole placement agent for the offering.
Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has entered into a placement agency agreement. The agreement is for the purchase and sale of 8,106,584 shares of its common stock (or prefunded warrants in lieu thereof). The shares are offered at $0.55 per share (or $0.549 per prefunded warrant in lieu thereof). According to the announcement, the offering is expected to close on or about Sept. 5, 2024. Gross proceeds of the offering, which will be subject to customary closing conditions, are estimated to be approximately $4.45 million before deduction of standard fees and expenses. Oragenics anticipates using the funds from the offering for the continued development of its ONP-002 product candidate as well as for general corporate purposes and working capital. Dawson James Securities Inc. is acting as the sole placement agent for the offering.
Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has completed its spray-dried formulation and filling of the nasal device for its lead candidate, ONP-002, for the treatment of concussion. A new chemical entity, ONP-002 targets the brain through delivery into the nasal cavity. According to the announcement, the prefilled formulation will be used to provide dosing for the upcoming phase 2a clinical trial in concussed patients.
Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has released a business status update. According to the update, which outlines key 2024 progress, the company continues to move forward on developing and advancing its lead candidate, ONP-002, for the treatment of concussion. Specifically, the update noted that phase 2 human trials are slated to begin in the fourth quarter of this year.
These companies are redefining market potential with innovation-driven growth and strategic advancements, presenting attractive opportunities for savvy investors seeking to capitalize on emerging trends and market dynamics.
Oragenics announced its lead candidate, ONP-002, for treating concussion, which shows no cardiotoxicity in studies. Designed for nasal delivery to the brain, ONP-002 aims to address the significant unmet medical need for concussion treatment.
